Please login to the form below

Not currently logged in
Email:
Password:

IO

This page shows the latest IO news and features for those working in and with pharma, biotech and healthcare.

Celgene boosts IO presence with Immatics deal

Celgene boosts IO presence with Immatics deal

Immatics technology promises to go beyond CAR-T capabilities. Celgene is not slowing down its strategic deals ahead of its merger with Bristol-Myers Squibb, and has strengthened its immunotherapy (IO)

Latest news

More from news
Approximately 6 fully matching, plus 14 partially matching documents found.

Latest Intelligence

  • Immuno-oncology in 2019: the rapid evolution continues Immuno-oncology in 2019: the rapid evolution continues

    However, the company continues to study Opdivo in trials twinned with a very wide range of novel agents, with the hope of finding a combination which can take immuno-oncology (IO)

  • Immunotherapy combination trials Q&A Immunotherapy combination trials Q&A

    What factors should sponsors weigh up when planning a new IO trial in 2019 and beyond? ... Through these concerted efforts, meaningful progress in IO will have its best chance.

  • Drug launches to watch in 2019 Drug launches to watch in 2019

    Merck/MSD looks to have gained a dominant position in checkpoint inhibitor immuno-oncology (IO) with Keytruda – but there remains room for growth in the market via new IO agents. ... This is particularly the case for the considerable percentage of

  • AstraZeneca’s oncology renaissance AstraZeneca’s oncology renaissance

    Of course, AstraZeneca isn’t immune to the setbacks of old – its IO drug Imfinzi is witness to that. ... This gives it a unique niche in an IO lung cancer market dominated by Merck &Co’s Keytruda, and prevented it from being an also-ran.

  • Communication is the key to unlocking the potential of immuno-oncology Communication is the key to unlocking the potential of immuno-oncology

    David Hunt, CEO, Havas Lynx Group. This new treatment – immuno-oncology (IO) – is revolutionising cancer care. ... data and insights; and lifting the veil on the IO field for patients.

More from intelligence
Approximately 2 fully matching, plus 8 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest from PMHub

  • Medical Device Clinical Trials 2020 Medical Device Clinical Trials 2020

    In July 2020, we attended and exhibited at the Medical Device Clinical Trials 2020 Virtual Experience. We really enjoyed the day and it was great to hear from like-minded people, while catching up on the latest in the industry. Here, we’ve

  • New Leaf Technology Solutions Ltd

    Before founding New Leaf Technology Solutions, Simon Chambers and his co-founder worked for a decade exclusively with the Pharmaceutical Industry, leading and delivering cutting edge business applications targeting the SFE market in areas such as

  • 18 SWITCHED ONcology: The Big Communication

    Yet IO is still a story of two extremes. At one end of the spectrum comes the success. ... But with the age of IO, the need and complexity is far greater.

  • Immuno-oncology; bringing patients closer to treatment

    Immuno-oncology (IO) is such an exciting area, especially for a patient. ... There’s been significant media coverage on the development of IO, on the so-called “super-patients,” and the possible outcomes that can be achieved; predominantly the

  • Physicians Interactive Becomes Aptus Health, Offering a Global Digital Health Engagement Solution

    To better reflect its role as a partner for global digital health engagement, Physicians Interactive recently announced it is now Aptus Health. The change comes as the company extends into new geographic markets and expands its offerings to address

More from PMHub
Approximately 1 fully matching, plus 11 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Wilmington Healthcare

A heritage to envy Wilmington Healthcare brings together the data intelligence specialisms of Binley’s, NHiS, Wellards and HSJ to create...

Latest intelligence

Could formulary intelligence be your brand differentiator?
Proprietary research, and the COVID-19 experience, shows how formulary intelligence can drive competitive advantage at launch...
Lara Meyer
How COVID-19 is accelerating the threat of antimicrobial resistance
Why antimicrobial resistance needs to be addressed with the same urgency as COVID-19...
Improve clinical trials through patient journey mapping
Could patient journey mapping be your solution to improving clinical study recruitment and retention? While awareness of clinical studies is low across the population, it’s not the only issue. It’s...

Infographics